Endometriosis Treatment Market Oral Contraceptives Remain a Preferred Treatment for Pelvic Pain and Endometriosis, Despite Potential Side Effects

The Endometriosis Treatment Market is charting a course for stable expansion, fueled by growing awareness and a rise in diagnosed cases. According to a recent analysis by Future Market Insights (FMI), a leading market research firm, the market is projected to exhibit a Compound Annual Growth Rate (CAGR) of approximately 3% from 2019 to 2030. This consistent growth trajectory is expected to propel the market valuation to surpass US$4 billion by the end of the forecast period, reflecting a significant increase from US$2.8 billion in 2018.

The steadfast growth of this industry is propelled by the escalating prevalence of endometriosis, a condition affecting millions of women worldwide. As the demand for advanced treatment options continues to surge, industry leaders are taking the helm, focusing on pioneering therapeutic advancements and strategic product launches.

Key Takeaways of Endometriosis Treatment Market Study

• Based on the drug, oral contraceptives contributed maximum value share to the global endometriosis treatment Industry in 2018, owing to a high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing the recurrence of pelvic pain and endometriosis lesions.
• High treatment efficacy and acceptance with low risk are expected to result in a notable share of hormonal therapy in the treatment type.
• The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of the value share of the endometriosis treatment industry, owing to the high patient pool in hospitals and visiting retail pharmacies.
• Europe captured a notable revenue share of 37% in 2018 and is expected to be the most lucrative region in the global endometriosis treatment market during the forecast period.
• Increasing government expenditure for the high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment industry across this region.

Oral contraceptives continue to be a highly preferred first-line treatment for patients with pelvic pain and endometriosis, particularly for those without contraindications. Known for their effectiveness in preventing the recurrence of pelvic pain and the growth of endometriosis lesions, these medications offer significant relief for many women suffering from these conditions.

However, while oral contraceptives are widely used, they are not without potential side effects. Patients may experience mood changes, nausea, and elevated blood pressure levels, which can affect their quality of life. These side effects should be carefully considered by healthcare providers when recommending oral contraceptives to patients.

Progestins as an Alternative Treatment
In contrast to oral contraceptives, progestins—another form of hormonal therapy—require periodic consumption rather than the regular daily use of oral contraceptives. While progestins may offer benefits in managing symptoms of endometriosis and pelvic pain, they also come with their own set of considerations and should be used as part of a comprehensive treatment plan tailored to the patient’s needs.

Key Considerations for Treatment Choices:

• Efficacy vs. Side Effects: While oral contraceptives are effective in managing endometriosis, it’s important for patients and healthcare providers to weigh the benefits against potential side effects.
• Personalized Treatment Plans: As treatment options evolve, a more personalized approach that considers the patient’s health profile, symptom severity, and lifestyle is essential.
• Alternative Therapies: Progestins and other therapies should be discussed as potential alternatives for patients who may experience intolerable side effects from oral contraceptives.

Grab Your Complete Report Instantly

Market segmentation

The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

By Drug:

• Oral Contraceptives
• Progestins
• NSAIDs
• GnRH Analogues
• LNR-IUDs
• Others

By Treatment Type:

• Hormonal Therapy
• Pain Management

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drugstores
• e-Commerce

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)